A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

✍ Scribed by Konstan, M.W.; Döring, G.; Heltshe, S.L.; Lands, L.C.; Hilliard, K.A.; Koker, P.; Bhattacharya, S.; Staab, A.; Hamilton, A.

• Book ID: 122427855
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 392 KB
• Volume: 13
• Category: Article
• ISSN: 1569-1993
• DOI: 10.1016/j.jcf.2013.12.009